» Articles » PMID: 37577216

Histopathological Features Predicting Long-term Clinical Outcomes in Patients with Vanishing Bile Duct Syndrome

Overview
Specialty Gastroenterology
Date 2023 Aug 14
PMID 37577216
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: The clinicopathological features and long-term outcomes of patients with vanishing bile duct syndrome (VBDS) have yet to be elucidated. The study aims to investigate these features and identify factors associated with poor prognosis.

Methods: This multicenter retrospective study recruited patients with liver biopsy-proven VBDS who were followed up at five hospitals in northern China from January 2003 to April 2022. Clinical and pathological data at time of biopsy were reviewed. Clinical outcomes including cirrhosis, decompensation events, liver transplantation (LT), and liver-related death were recorded. Cox regression analysis was used to identify the risk factors associated with poor outcomes.

Results: A total of 183 patients were included. The median age was 47 years, with 77.6% being women. During a median follow-up of 4.8 years, 88 patients developed compensated or decompensated cirrhosis, 27 died, and 15 received LT. Multivariate Cox regression analysis showed that hepatocellular cholestasis (HR 2.953, 95% CI: 1.437-6.069), foam cells (HR 2.349, 95% CI: 1.092-5.053), and advanced fibrosis (HR 2.524, 95% CI: 1.313-4.851) were independent predictors of LT or liver-related deaths. A nomogram formulated with the above factors showed good consistency with a concordance index of 0.746 (95% CI: 0.706-0.785).

Conclusions: Nearly half of VBDS patients studied progressed to end-stage liver disease and 23% of them had LT or liver-related death within two years of diagnosis. Hepatocellular cholestasis, foam cells and advanced fibrosis rather than the degree of bile duct loss or underlying etiologies were independently associated with poor prognosis in VBDS patients.

Citing Articles

Clinicopathologic Features of a Rare and Underrecognized Variant of Early-stage Primary Biliary Cholangitis With Ductopenia.

Yu H, Lv T, Li S, Chen S, Li M, Liu J Am J Surg Pathol. 2024; 49(3):265-272.

PMID: 39704223 PMC: 11834957. DOI: 10.1097/PAS.0000000000002343.

References
1.
You H, Ma X, Efe C, Wang G, Jeong S, Abe K . APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int. 2022; 16(1):1-23. PMC: 8843914. DOI: 10.1007/s12072-021-10276-6. View

2.
De Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C . Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022; 76(4):959-974. PMC: 11090185. DOI: 10.1016/j.jhep.2021.12.022. View

3.
Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L . Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology. 2001; 33(3):633-46. DOI: 10.1053/jhep.2001.22646. View

4.
Steyerberg E, Vergouwe Y . Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014; 35(29):1925-31. PMC: 4155437. DOI: 10.1093/eurheartj/ehu207. View

5.
Tian Q, Zhao X, Wang Y, Wee A, Soon G, Gouw A . Histologic pattern is better correlated with clinical outcomes than biochemical classification in patients with drug-induced liver injury. Mod Pathol. 2019; 32(12):1795-1805. DOI: 10.1038/s41379-019-0314-9. View